1
|
Costello R, O'Connor M, McGarvey C. 320 IDENTIFYING OUTCOMES FOR PATIENTS LEAVING REHABILITATION WITHOUT THE MULTI-DISCIPLINARY TEAM (MDT) RECOMMENDED HOME CARE PACKAGE (HCP) HOURS IN PLACE. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Home-Care Packages (HCPs) aim to support older people to remain in their homes. The community care system in Ireland has a small range of services with inconsistent availability. This study aims to identify outcomes for patients leaving rehabilitation without the MDT recommended HCP.
Methods
Demographics of patients discharged from rehab January 2021 to December 2021 were collected. Patients were classified into those with and without recommended HCP at time of discharge. Telephone consultations were held and data collected including; number of falls since discharge and EQ-ED-5L quality of life questionnaires were completed.
Results
Of 30 patients included (aged 66-94), 9 did not have full HCP hours on discharge. The range of Length of Stay (LoS) was 2-120 days in the correct HCP group and 7-59 in the incorrect HCP group. There was 7 readmissions to hospital, 5 from full HCP group. Three patients had a fall since discharge. In the correct HCP group, 42% had a mobility score of 3 or greater and 38% had a self-care score of 3 or greater. This was 11% and 33% respectfully in the incorrect HCP group.
Conclusion
Those who were discharged with full HCP had larger range of LoS. All patients who suffered falls were in the full HCP group. Incorrect HCP group had better scores in mobility and self-care. There were low rates of readmission to hospital in this group of patients discharged following a period of rehabilitation.
Collapse
Affiliation(s)
- R Costello
- National Orthopaedic Hospital Cappagh , Dublin, Ireland
- Connolly Hospital Blanchardstown , Dublin, Ireland
| | - M O'Connor
- National Orthopaedic Hospital Cappagh , Dublin, Ireland
- Connolly Hospital Blanchardstown , Dublin, Ireland
| | - C McGarvey
- National Orthopaedic Hospital Cappagh , Dublin, Ireland
- Connolly Hospital Blanchardstown , Dublin, Ireland
| |
Collapse
|
2
|
McGarvey C, Larkin J, Costello R, Connor MO. 164 OLDER PATIENTS AT THE PREOPERATIVE ASSESSMENT CLINIC: CHANGING THE FOCUS FROM FIT FOR SURGERY TO OPTIMISATION FOR SURGERY. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The Pre-operative Assessment Clinic (PAC) is run by the Anaesthetic Department and assesses older patients undergoing elective orthopaedic surgery. The aim of this study was to examine how PAC currently assesses older patients and how effective it is in assessing for likelihood of postoperative complications and requirement for rehabilitation.
Methods
A single-centre, retrospective study that received approval from the local ethics committee. Data were collected on all patients post elective orthopaedic surgery admitted to the on-site specialist rehabilitation unit for older persons, between 1st May 2020 and 31st December 2021. Data were collected from hospital Information Technology platform, Bluespiers.
Results
Seventy-six patients (58 female; median age: 80 years) were included. Median time from PAC to surgery was 95 days. Functional assessment was completed in 63.16% of cases, formal cognitive assessment was done in 13% of cases. Number of falls in the preceding year was recorded in 31% of patients. Baseline mobility was recorded in 93% of cases. Whilst smoking and alcohol history was recorded in 96% of cases, number of units was not calculated. 45% (n=34) of patients were correctly identified as likely to require post-operative inpatient rehabilitation. PAC did not record sarcopaenia, polypharmacy or delirium risk factors. From our dataset, at least 13% had sarcopaenia, 80% had polypharmacy and 23% required opiate medications. Post-operatively, 16% of patients developed a delirium and 12% had an acute kidney injury.
Conclusion
In its current format, PAC fails to optimally risk stratify frail, older patients. Attention concentrates on fitness for surgery rather than optimisation of patients. Failure to record frailty, sarcopenia, cognitive impairment and risk factors for delirium is leading to missed opportunities in terms of delirium prevention, and peri-operative optimisation of older patients as well as discharge planning before surgery. Collaboration with specialist geriatric services at PAC should improve patient outcomes.
Collapse
Affiliation(s)
- C McGarvey
- National Orthopaedic Hospital, Cappagh , Dublin, Ireland
| | - J Larkin
- National Orthopaedic Hospital, Cappagh , Dublin, Ireland
| | - R Costello
- National Orthopaedic Hospital, Cappagh , Dublin, Ireland
| | - MO Connor
- National Orthopaedic Hospital, Cappagh , Dublin, Ireland
| |
Collapse
|
3
|
McGarvey C, Larkin J, Costello R, Connor MO. 248 BENEFITS OF POST-OPERATIVE SPECIALIST GERIATRIC CARE FOR OLDER PATIENTS UNDERGOING ELECTIVE ORTHOPAEDIC SURGERY. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The Covid-19 pandemic changed work practices across many different healthcare institutions. The difficulties with cross-site transfers created an opportunity in our institution to provide on-site post-operative rehabilitation for older patients undergoing elective orthopaedic surgery. The aim of this study is to assess the impact of post-operative specialist geriatric care on older patients.
Methods
This is a single-centre, retrospective study that received approval from the local hospital ethics committee. Data were collected on all patients admitted to the on-site specialist rehabilitation unit post-elective orthopaedic surgery between 1st May 2020 and 31st December 2021. Two patients in this group were excluded as they had not attended a pre-operative assessment clinic. Data were collected from hospital Information Technology platform, Bluespiers.
Results
76 patients, 18 males and 58 females, were included in this study. The median age was 80 years. In the specialist rehabilitation unit, evidence of cognitive impairment was established in 40.79% of cases, there were 3 cases of newly diagnosed dementia, a history of falls was identified in 32.89% of patients and 13.16% of patients were found to have sarcopaenia. The median length of stay in the rehabilitation unit was 25 days. 51.32% of patients were discharged home independently, 23.68% of patients went home with a new Home-Care Package (HCP), 15.79% of patients were discharged home with an existing HCP, 6.58% of patients were transferred for further treatment and 2.63% patients were discharged to residential care units.
Conclusion
This data demonstrates a clear role for specialist geriatric care in elective rehabilitation, with a significant proportion of patients being discharged home independently. The benefits of a comprehensive geriatric assessment in the peri-operative setting include increased identification of cognitive impairment allowing appropriate implementation of brain health as well as identification of a history of falls, enabling falls risk assessment and management including bone health assessment.
Collapse
Affiliation(s)
- C McGarvey
- National Orthopaedic Hospital, Cappagh , Dublin, Ireland
| | - J Larkin
- National Orthopaedic Hospital, Cappagh , Dublin, Ireland
| | - R Costello
- National Orthopaedic Hospital, Cappagh , Dublin, Ireland
| | - MO Connor
- National Orthopaedic Hospital, Cappagh , Dublin, Ireland
| |
Collapse
|
4
|
Donnette M, Ciccolini J, Pissier C, Costello R, Duffaud F, Salas S, Farnault L, Tichadou A, Arcani R, Jarrot PA, Ouafik LH, Venton G, Fanciullino R. High incidence of CDA deficiency in patients with hematological malignancies: perspectives and therapeutic implications. Ann Oncol 2021; 32:684-686. [PMID: 33529741 DOI: 10.1016/j.annonc.2021.01.072] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2020] [Revised: 12/30/2020] [Accepted: 01/17/2021] [Indexed: 11/29/2022] Open
Affiliation(s)
- M Donnette
- SMARTc, Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Aix-Marseille University, Marseille, France
| | - J Ciccolini
- SMARTc, Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Aix-Marseille University, Marseille, France.
| | - C Pissier
- Laboratoire de Transfert en Oncologie, University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - R Costello
- Hematology Unit, La Conception University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - F Duffaud
- Medical Oncology Unit, La Timone University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - S Salas
- Medical Oncology Unit, La Timone University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - L Farnault
- Hematology Unit, La Conception University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - A Tichadou
- Hematology Unit, La Conception University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - R Arcani
- Internal Medicine Unit, La Conception University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - P A Jarrot
- Internal Medicine Unit, La Conception University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - L H Ouafik
- Laboratoire de Transfert en Oncologie, University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - G Venton
- Hematology Unit, La Conception University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - R Fanciullino
- SMARTc, Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Aix-Marseille University, Marseille, France
| |
Collapse
|
5
|
Carron J, Fitzgerald SJ, Costello R, Sheahan R. P338Dystrophin deficient cardiomyopathy: predictors associated with the cardiac phenotype in a Duchenne registry population - A guide for device therapy. Europace 2020. [DOI: 10.1093/europace/euaa162.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Patients with Duchenne muscular dystrophy (DMD) typically exhibit cardiac dysfunction. With increasing life expectancy due to advances in respiratory support, cardiomyopathy and associated dsyrhythmia are fast becoming the primary cause of morbidity and mortality in this patient group. Despite advances, the correlation between genotype and cardiac phenotype remains poorly understood and individual registries small, with implementation of device therapy often delayed due to poor diagnostic imaging.
Methods and Aims: A single-center registry for DMD patients was established and data including genotyping, medical therapy and investigations such as cardiac MRI, nt-Pro BNP levels, echocardiogram were analysed. The aim was to potentially identify predictors associated with a more severe cardiac phenotype and thus help to guide provision of device therapy.
Results
A total of 19 patients (age 17 - 31) with DMD were reviewed (demographics table 1). All patients were evaluated with echocardiography on at least one occasion (mean EF 46.5%). Cardiac MRI was attempted in 6 patients however only completed in 2 due to contractures preventing access to scanning. 11 of 19 patients (58%) demonstrated an impaired left ventricular ejection fraction (EF) <50% (mean EF 42%). Proximal "hot spot" mutations/deletions (exon 2-19) were associated with a more pronounced reduction in EF, all patients with proximal mutations demonstrating an EF < 45% (mean 41%). 5 of 6 (83%) of those with >1 exon deletion mutations demonstrated more severely impaired EF (mean EF 41%) compared to those with single exon deletions (mean EF 52%). Interestingly, one patient with a proximal mutation (exon 3-6 deletion) remains mobilising to distances of 70 meters, however cardiac MRI revealed a moderate degree of fibrosis with an EF of 43%. Correlation between nt-Pro BNP levels with reduced EF was not uniform, however a level < 100 was associated with an EF >55% in 89% of patients studied. of those on steroid regimes, 6 (54%) had impaired LVEF compared to 5 (83%) of those not on steroid therapy. All patients were on at least one class of heart failure modification, with 79% on two and 37% on three agents. Only one patient in the registry has had an ICD implanted. He has had a device for 10 years in and in this time there have been no therapies delivered however runs of non-sustained ventricular tachycardia have been noted.
Conclusions
Correlation between predictors and cardiac phenotype in a Duchenne population remains unreliable. Location and size of exon alteration appears to be indicative of more markedly impaired LV function, however larger studies are required to characterise this further and challenges remain with regard to accurate assessment of EF. The use of predictors in future may help to guide appropriate provision of device therapy.
Collapse
Affiliation(s)
- J Carron
- Beaumont Hospital, Dublin, Ireland
| | | | | | | |
Collapse
|
6
|
Humphries N, McDermott AM, Conway E, Byrne JP, Prihodova L, Costello R, Matthews A. 'Everything was just getting worse and worse': deteriorating job quality as a driver of doctor emigration from Ireland. Hum Resour Health 2019; 17:97. [PMID: 31815621 PMCID: PMC6902557 DOI: 10.1186/s12960-019-0424-y] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Accepted: 10/21/2019] [Indexed: 05/28/2023]
Abstract
BACKGROUND Medicine is a high-status, high-skill occupation which has traditionally provided access to good quality jobs and relatively high salaries. In Ireland, historic underfunding combined with austerity-related cutbacks has negatively impacted job quality to the extent that hospital medical jobs have begun to resemble extreme jobs. Extreme jobs combine components of a good quality job-high pay, high job control, challenging demands, with those of a low-quality job-long working hours, heavy workloads. Deteriorating job quality and the normalisation of extreme working is driving doctor emigration from Ireland and deterring return. METHODS Semi-structured qualitative interviews were conducted with 40 Irish emigrant doctors in Australia who had emigrated from Ireland since 2008. Interviews were held in July-August 2018. RESULTS Respondents reflected on their experiences of working in the Irish health system, describing hospital workplaces that were understaffed, overstretched and within which extreme working had become normalised, particularly in relation to long working hours, fast working pace, doing more with less and fighting a climate of negativity. Drawing on Hirschman's work on exit, voice and loyalty (1970), the authors consider doctor emigration as exit and present respondent experiences of voice prior to emigration. Only 14/40 respondent emigrant doctors intend to return to work in Ireland. DISCUSSION The deterioration in medical job quality and the normalisation of extreme working is a key driver of doctor emigration from Ireland, and deterring return. Irish trained hospital doctors emigrate to access good quality jobs in Australia and are increasingly likely to remain abroad once they have secured them. To improve doctor retention, health systems and employers must mitigate a gainst the emergence of extreme work in healthcare. Employee voice (about working conditions, about patient safety, etc.) should be encouraged and used to inform health system improvement and to mitigate exit.
Collapse
Affiliation(s)
- N Humphries
- Research Royal College of Physicians of Ireland, Dublin, Ireland.
| | - A M McDermott
- Cardiff Business School, Cardiff University, Cardiff, UK
| | - E Conway
- Dublin City University Business School, Dublin City University, Dublin, Ireland
| | - J-P Byrne
- Research Royal College of Physicians of Ireland, Dublin, Ireland
| | - L Prihodova
- Research Royal College of Physicians of Ireland, Dublin, Ireland
| | - R Costello
- Royal College of Surgeons in Ireland, Dublin, Ireland
| | - A Matthews
- School of Nursing, Psychotherapy and Community Health, Dublin City University, Dublin, Ireland
| |
Collapse
|
7
|
Wigdahl B, Chung CH, Allen A, Atkins A, Costello R, Sullivan N, Nonnemacher M, Dampier W. CRISPR/Cas9 editing of HIV-1 transcription factor binding sites on the 5’ long terminal repeats to permanently inactivate latent provirus. J Virus Erad 2019. [DOI: 10.1016/s2055-6640(20)30218-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
8
|
Denis G, Sanhes L, Ziza J, Bauduer F, Berger M, Costello R, Mehdi K, Michaud M, Urbanski G, Rose C. Le challenge des splénomégalies inexpliquées : premières données de l’étude prospective multicentrique SMS (SplenoMegalyStudy). Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.03.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
9
|
Venton G, Suchon P, Colle J, Baier C, Sanderson F, Poullin P, Ivanov V, Mercier C, Farnault L, Roche P, Arcani R, Fanciullino R, Brunet C, Philip PJM, Costello R. Hematopoietic reconstitution after autologous hematopoietic stem cell transplantation: do CD45 (+) CD34 (+) CD38 (-) progenitors really matter in real life? Transfus Apher Sci 2018; 57:406-408. [PMID: 29709543 DOI: 10.1016/j.transci.2018.04.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2018] [Revised: 03/30/2018] [Accepted: 04/04/2018] [Indexed: 10/17/2022]
Affiliation(s)
- G Venton
- INSERM, UMR1090 TAGC,Marseille, F_13288,France; Aix-Marseille University, UMR1090 TAGC,Marseille, F_13288,France; Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France
| | - P Suchon
- Hematology laboratory, La Timone, University Hospital of Marseille, France; UMR 1062 NORT, INSERM, Marseille France
| | - J Colle
- INSERM, UMR1090 TAGC,Marseille, F_13288,France; Aix-Marseille University, UMR1090 TAGC,Marseille, F_13288,France; Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France
| | - C Baier
- INSERM, UMR1090 TAGC,Marseille, F_13288,France
| | - F Sanderson
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France; Apheresis and auto transfusion department, la Conception, University Hospital of Marseille, France
| | - P Poullin
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France; Apheresis and auto transfusion department, la Conception, University Hospital of Marseille, France
| | - V Ivanov
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France
| | - C Mercier
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France; UMR-911 INSERM, Toxicokinetics andpharmacokinetics laboratory, pharmacological faculty, Marseille, France
| | - L Farnault
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France
| | - P Roche
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France
| | - R Arcani
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France
| | - R Fanciullino
- SMARTc Unit, Pharmacokinetics Laboratory, UMR_911 CRO2 AMU Marseille, France; Pharmacy Unit, La Conception University Hospital of Marseille, APHM, Marseille, France
| | - C Brunet
- Hematology laboratory, La Conception, University Hospital of Marseille, France
| | - P J M Philip
- Cell therapy unit - The French Blood Establishment (EFS - Provence - Alpes Côte d'Azur - Corse)", Saint Laurent du Var, France
| | - R Costello
- INSERM, UMR1090 TAGC,Marseille, F_13288,France; Aix-Marseille University, UMR1090 TAGC,Marseille, F_13288,France; Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France.
| |
Collapse
|
10
|
Landgren O, Graubard BI, Kumar S, Kyle RA, Katzmann JA, Murata K, Costello R, Dispenzieri A, Caporaso N, Mailankody S, Korde N, Hultcrantz M, Therneau TM, Larson DR, Cerhan JR, Rajkumar SV. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey. Blood Cancer J 2017; 7:e618. [PMID: 29053158 PMCID: PMC5678222 DOI: 10.1038/bcj.2017.97] [Citation(s) in RCA: 67] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2017] [Accepted: 08/03/2017] [Indexed: 01/20/2023] Open
Abstract
We studied the prevalence of monoclonal gammopathy of undetermined significance (MGUS) in younger individuals, age 10–49 years, using samples from the National Health and Nutritional Examination Survey (NHANES) III. NHANES prevalence rates were standardized to the 2000 US total population. Among 12 372 individuals (4073 blacks, 4146 Mexican-Americans, 3595 whites, and 558 others), MGUS was identified in 63 persons (0.34%, 95% CI 0.23–0.50). The prevalence of MGUS was significantly higher in blacks (0.88%, 95% CI 0.62–1.26) compared with whites (0.22%, 95% CI 0.11–0.45), P=0.001. The prevalence of MGUS in Mexican-Americans was at an intermediate level (0.41%, 95% CI 0.23–0.73). The disparity in prevalence of MGUS between blacks and whites was most striking in the 40–49 age-group; 3.26% (95% CI 2.04–5.18) versus 0.53% (95% CI 0.20–1.37), P=0.0013. There was a trend to earlier age of onset of MGUS in blacks compared with whites. MGUS was seen in only two persons in the 10–19 age-group (both Mexican-American), and in three persons in the 20–29-year age-group (all of whom were black). In persons less than 50 years of age, MGUS is significantly more prevalent, with up to 10 years earlier age of onset, in blacks compared with whites.
Collapse
Affiliation(s)
- O Landgren
- Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - B I Graubard
- Divsion of Cancer Epidemiology and Genetics, Biostatistics Branch, National Cancer Institute, Rockville, MD, USA
| | - S Kumar
- Division of Hematology, Department of Medicine, College of Medicine, Mayo Clinic, Rochester, MN, USA
| | - R A Kyle
- Division of Hematology, Department of Medicine, College of Medicine, Mayo Clinic, Rochester, MN, USA
| | - J A Katzmann
- Department of Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, Rochester, MN, USA
| | - K Murata
- Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - R Costello
- Multiple Myeloma Section, Center for Cancer Research, Lymphoid Malignancies Branch, National Cancer Institute, Rockville, MD, USA
| | - A Dispenzieri
- Division of Hematology, Department of Medicine, College of Medicine, Mayo Clinic, Rochester, MN, USA
| | - N Caporaso
- Divsion of Cancer Epidemiology and Genetics, Biostatistics Branch, National Cancer Institute, Rockville, MD, USA
| | - S Mailankody
- Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - N Korde
- Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - M Hultcrantz
- Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - T M Therneau
- Division of Biostatistics, Department of Medicine, College of Medicine, Mayo Clinic, Rochester, MN, USA
| | - D R Larson
- Division of Biostatistics, Department of Medicine, College of Medicine, Mayo Clinic, Rochester, MN, USA
| | - J R Cerhan
- Division of Epidemiology, Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, MN, USA
| | - S V Rajkumar
- Division of Hematology, Department of Medicine, College of Medicine, Mayo Clinic, Rochester, MN, USA
| |
Collapse
|
11
|
Nadal R, Mortazavi A, Stein M, Pal S, Davarpanah N, Parnes H, Ning Y, Cordes L, Lin J, Bagheri M, Linderberg L, Berniger M, Steinberg S, Moore T, Lancaster T, Aviles M, Costello R, Bottaro D, Dahut W, Apolo A. Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx371.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Pérez-Alea M, McGrail K, Sánchez-Redondo S, Ferrer B, Fournet G, Cortés J, Muñoz E, Hernandez-Losa J, Tenbaum S, Martin G, Costello R, Ceylan I, Garcia-Patos V, Recio JA. ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment. Oncogene 2017; 36:5695-5708. [PMID: 28581514 DOI: 10.1038/onc.2017.160] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2016] [Revised: 04/18/2017] [Accepted: 04/18/2017] [Indexed: 12/12/2022]
Abstract
Despite the promising targeted and immune-based interventions in melanoma treatment, long-lasting responses are limited. Melanoma cells present an aberrant redox state that leads to the production of toxic aldehydes that must be converted into less reactive molecules. Targeting the detoxification machinery constitutes a novel therapeutic avenue for melanoma. Here, using 56 cell lines representing nine different tumor types, we demonstrate that melanoma cells exhibit a strong correlation between reactive oxygen species amounts and aldehyde dehydrogenase 1 (ALDH1) activity. We found that ALDH1A3 is upregulated by epigenetic mechanisms in melanoma cells compared with normal melanocytes. Furthermore, it is highly expressed in a large percentage of human nevi and melanomas during melanocyte transformation, which is consistent with the data from the TCGA, CCLE and protein atlas databases. Melanoma treatment with the novel irreversible isoform-specific ALDH1 inhibitor [4-dimethylamino-4-methyl-pent-2-ynthioic acid-S methylester] di-methyl-ampal-thio-ester (DIMATE) or depletion of ALDH1A1 and/or ALDH1A3, promoted the accumulation of apoptogenic aldehydes leading to apoptosis and tumor growth inhibition in immunocompetent, immunosuppressed and patient-derived xenograft mouse models. Interestingly, DIMATE also targeted the slow cycling label-retaining tumor cell population containing the tumorigenic and chemoresistant cells. Our findings suggest that aldehyde detoxification is relevant metabolic mechanism in melanoma cells, which can be used as a novel approach for melanoma treatment.
Collapse
Affiliation(s)
- M Pérez-Alea
- Biomedical Research in Melanoma-Animal Models and Cancer Laboratory-Oncology Program, Vall d'Hebron Research institute VHIR-Vall d'Hebron Hospital, Barcelona-UAB, Spain
| | - K McGrail
- Biomedical Research in Melanoma-Animal Models and Cancer Laboratory-Oncology Program, Vall d'Hebron Research institute VHIR-Vall d'Hebron Hospital, Barcelona-UAB, Spain
| | - S Sánchez-Redondo
- Biomedical Research in Melanoma-Animal Models and Cancer Laboratory-Oncology Program, Vall d'Hebron Research institute VHIR-Vall d'Hebron Hospital, Barcelona-UAB, Spain
| | - B Ferrer
- Biomedical Research in Melanoma-Animal Models and Cancer Laboratory-Oncology Program, Vall d'Hebron Research institute VHIR-Vall d'Hebron Hospital, Barcelona-UAB, Spain.,Anatomy Pathology Department, Vall d'Hebron Hospital, Barcelona-UAB, Spain
| | - G Fournet
- Institut de Chimie et Biochimie Moléculaire et Supramoléculaire, UMR-CNRS 5246, Université de Lyon, Université Claude Bernard-Lyon1, Villeurbanne, France
| | - J Cortés
- Ramon y Cajal University Hospital, Madrid, Spain.,Clinical Oncology Program, Vall d'Hebron Institute of Oncology-VHIO, Vall d'Hebron Hospital, Barcelona-UAB, Spain
| | - E Muñoz
- Clinical Oncology Program, Vall d'Hebron Institute of Oncology-VHIO, Vall d'Hebron Hospital, Barcelona-UAB, Spain
| | - J Hernandez-Losa
- Anatomy Pathology Department, Vall d'Hebron Hospital, Barcelona-UAB, Spain
| | - S Tenbaum
- Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - G Martin
- Advanced BioDesign, Parc Technologique de Lyon, Woodstock - Bâtiment Cèdre 1, Saint Priest, France
| | - R Costello
- Service d'Hématologie et Thérapie Cellulaire, Centre Hospitalier Universitaire La Conception, Marseille, France
| | - I Ceylan
- Advanced BioDesign, Parc Technologique de Lyon, Woodstock - Bâtiment Cèdre 1, Saint Priest, France
| | - V Garcia-Patos
- Biomedical Research in Melanoma-Animal Models and Cancer Laboratory-Oncology Program, Vall d'Hebron Research institute VHIR-Vall d'Hebron Hospital, Barcelona-UAB, Spain.,Dermatology Department, Vall d'Hebron Hospital, Barcelona-UAB, Spain
| | - J A Recio
- Biomedical Research in Melanoma-Animal Models and Cancer Laboratory-Oncology Program, Vall d'Hebron Research institute VHIR-Vall d'Hebron Hospital, Barcelona-UAB, Spain
| |
Collapse
|
13
|
Yap D, Shakir A, Costello R, Browning S. Fitness to drive-How well do we know the rules? Survey of 19 ENT surgeons in Wales. Clin Otolaryngol 2017; 42:1078-1081. [PMID: 28207987 DOI: 10.1111/coa.12852] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/11/2017] [Indexed: 11/26/2022]
Affiliation(s)
- D Yap
- Department of ENT, Royal Gwent Hospital, Newport, UK
| | - A Shakir
- Department of Otolaryngology and Head and Neck Surgery, Singleton Hospital, Swansea, UK
| | - R Costello
- Department of ENT, Royal Gwent Hospital, Newport, UK
| | - S Browning
- Department of Otolaryngology and Head and Neck Surgery, Singleton Hospital, Swansea, UK
| |
Collapse
|
14
|
Lucey D, Sholts S, Blond K, Costello R, Murray S. Exploring epidemics: A Smithsonian museum endeavor for the public. Int J Infect Dis 2016. [DOI: 10.1016/j.ijid.2016.11.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
15
|
Schuttler SG, Parsons AW, Forrester TD, Baker MC, McShea WJ, Costello R, Kays R. Deer on the lookout: how hunting, hiking and coyotes affect white‐tailed deer vigilance. J Zool (1987) 2016. [DOI: 10.1111/jzo.12416] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
| | - A. W. Parsons
- North Carolina Museum of Natural Sciences Raleigh NC USA
| | - T. D. Forrester
- Smithsonian Conservation Biology Institute Front Royal VA USA
- Oregon Department of Fish and Wildlife La Grande OR USA
| | - M. C. Baker
- Smithsonian Conservation Biology Institute Front Royal VA USA
- The Nature Conservancy Arlington VA USA
| | - W. J. McShea
- Smithsonian Conservation Biology Institute Front Royal VA USA
| | - R. Costello
- Smithsonian National Museum of Natural History Washington DC USA
| | - R. Kays
- North Carolina Museum of Natural Sciences Raleigh NC USA
- Smithsonian National Museum of Natural History Washington DC USA
- Department of Forestry & Environmental Resources North Carolina State University Raleigh NC USA
| |
Collapse
|
16
|
Apolo A, Mortazavi A, Stein M, Pal S, Davarpanah N, Parnes H, Ning Y, Francis D, Cordes L, Berniger M, Steinberg S, Monk P, Lancaster T, Mayer T, Costello R, Bottaro D, Dahut W. A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw373.02] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Nadal R, Parnes H, Francis D, Cordes L, Berninger M, Costello R, Folio L, Linderberg M, Machado L, Steinberg S, Wright J, Ning Y, Bottaro D, Dahut W, Apolo A. A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw373.15] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Costello R, Prabhu V, Whittet H. Lingual tonsil: clinically applicable macroscopic anatomical classification system. Clin Otolaryngol 2016; 42:144-147. [DOI: 10.1111/coa.12715] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/12/2016] [Indexed: 11/27/2022]
Affiliation(s)
- R. Costello
- ENT Department; Singleton Hospital; Swansea UK
| | - V. Prabhu
- ENT Head and Neck Department; Singleton Hospital; Swansea UK
| | - H. Whittet
- ENT Head and Neck Department; Singleton Hospital; Swansea UK
| |
Collapse
|
19
|
Sanderson F, Poullin P, Smith R, Nicolino-Brunet C, Philip P, Chaib A, Costello R. Peripheral blood stem cells collection on spectra optia apheresis system using the continuous mononuclear cell collection protocol: A single center report of 39 procedures. J Clin Apher 2016; 32:182-190. [DOI: 10.1002/jca.21485] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2016] [Revised: 06/16/2016] [Accepted: 06/30/2016] [Indexed: 12/19/2022]
Affiliation(s)
- F. Sanderson
- CHU La Conception; Service d'hémaphérèse Auto Transfusion
| | - P. Poullin
- CHU La Conception; Service d'hémaphérèse Auto Transfusion
| | - R. Smith
- Terumo BCT; Lakewood Colorado USA
| | | | - P. Philip
- Etablissement Français Du Sang Alpes Méditerranée; Saint Laurent du Var
| | - A. Chaib
- Service d'hématologie oncologie; Aix-en-Provence
| | - R. Costello
- CHU La Conception; Service d'hématologie et de thérapie cellulaire
| |
Collapse
|
20
|
Venton G, Adam H, Colle J, Labiad Y, Mercier C, Ivanov V, Suchon P, Fanciullino R, Farnault L, Costello R. Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemia. Med Mal Infect 2016; 46:226-9. [PMID: 27126350 DOI: 10.1016/j.medmal.2016.03.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2015] [Revised: 01/29/2016] [Accepted: 03/18/2016] [Indexed: 10/21/2022]
Abstract
OBJECTIVE To study the efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing induction chemotherapy for acute myeloid leukemia. PATIENTS AND METHODS A prospective observational single-center study of 41 patients from the hematology department between May 2012 and April 2015. Micafungin was administered once daily from the first day of induction chemotherapy to the end of the neutropenic phase. RESULTS Neither Candida nor Aspergillus infection was documented in our 41 patients from the first day of micafungin infusion to the end of the neutropenic phase. Patients were followed for three months after discontinuation of micafungin and none of them contracted an invasive fungal infection. Only one patient presented with grade III-IV hepatic and ionic toxicities. CONCLUSION Micafungin is associated with a good safety profile and is an interesting option for preventing invasive fungal infections in the high-risk population of patients presenting with hematological disorders.
Collapse
Affiliation(s)
- G Venton
- Inserm, UMR1090 TAGC, 13288 Marseille, France; Aix-Marseille université, UMR1090 TAGC, 13288 Marseille, France; Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France
| | - H Adam
- Unité pharmacie hospitalière hôpital de la Conception, Marseille, France
| | - J Colle
- Inserm, UMR1090 TAGC, 13288 Marseille, France; Aix-Marseille université, UMR1090 TAGC, 13288 Marseille, France; Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France
| | - Y Labiad
- Inserm, UMR1090 TAGC, 13288 Marseille, France; Aix-Marseille université, UMR1090 TAGC, 13288 Marseille, France
| | - C Mercier
- Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France; UMR-911 Inserm laboratoire de toxicocinétique et pharmacocinétique, faculté de pharmacie, Marseille, France
| | - V Ivanov
- Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France
| | - P Suchon
- Laboratoire d'hématologie, AP-HM, hôpital de la Timone, Marseille, France; UMR 1062 NORT, Inserm, Marseille, France
| | - R Fanciullino
- UMR-911 Inserm laboratoire de toxicocinétique et pharmacocinétique, faculté de pharmacie, Marseille, France; Unité pharmacie hospitalière hôpital de la Conception, Marseille, France
| | - L Farnault
- Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France
| | - R Costello
- Inserm, UMR1090 TAGC, 13288 Marseille, France; Aix-Marseille université, UMR1090 TAGC, 13288 Marseille, France; Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France.
| |
Collapse
|
21
|
Costello R, Whittet H. Use of Provisc ® eye protection during FESS. Clin Otolaryngol 2016; 42:197-198. [PMID: 26586368 DOI: 10.1111/coa.12474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/26/2015] [Indexed: 12/01/2022]
Affiliation(s)
- R Costello
- Ear, Nose and Throat Department, Singleton Hospital, Swansea, UK
| | - H Whittet
- Ear, Nose and Throat Department, Singleton Hospital, Swansea, UK
| |
Collapse
|
22
|
Julien M, Meunier B, Retornaz F, Costello R, Mancini J, Mazodier K, Jean R, Durand J, Kaplanski G, Chiche L. Prise en charge des gammapathies monoclonales dépistées en médecine générale : étude des pratiques en médecine interne. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.03.283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
23
|
Costello R, Winthrop K, Pye S, Dixon W. OP0301 Vaccination Uptake in Patients with Rheumatoid Arthritis Treated with Disease-Modifying Anti-Rheumatic Drug Therapy: A Retrospective Cohort Study Using UK Primary Care Electronic Medical Records. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
24
|
Gusev P, Andrews K, Palachuvattil J, Dang P, Savarala S, Han F, Pehrsson P, Douglass L, Dwyer J, Betz J, Saldanha L, Costello R, Bailey R. Analytical Content of Multivitamin/Mineral (MVM) Products Manufactured for Different Consumer Categories. FASEB J 2015. [DOI: 10.1096/fasebj.29.1_supplement.586.6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P Gusev
- Nutrient Data LaboratoryBHNRC, ARS, USDABeltsvilleMDUnited States
| | - K Andrews
- Nutrient Data LaboratoryBHNRC, ARS, USDABeltsvilleMDUnited States
| | - J Palachuvattil
- Nutrient Data LaboratoryBHNRC, ARS, USDABeltsvilleMDUnited States
| | - P Dang
- Nutrient Data LaboratoryBHNRC, ARS, USDABeltsvilleMDUnited States
| | - S Savarala
- Nutrient Data LaboratoryBHNRC, ARS, USDABeltsvilleMDUnited States
| | - F Han
- Nutrient Data LaboratoryBHNRC, ARS, USDABeltsvilleMDUnited States
| | - P Pehrsson
- Nutrient Data LaboratoryBHNRC, ARS, USDABeltsvilleMDUnited States
| | - L Douglass
- Statistician ConsultantLongmontCOUnited States
| | - J Dwyer
- Office of Dietary SupplementsNIH, DHHSBethesdaMDUnited States
| | - J Betz
- Office of Dietary SupplementsNIH, DHHSBethesdaMDUnited States
| | - L Saldanha
- Office of Dietary SupplementsNIH, DHHSBethesdaMDUnited States
| | - R Costello
- Office of Dietary SupplementsNIH, DHHSBethesdaMDUnited States
| | - R Bailey
- Office of Dietary SupplementsNIH, DHHSBethesdaMDUnited States
| |
Collapse
|
25
|
Saldanha L, Dwyer J, Andrews K, Bailen R, Bailey R, Betz J, Costello R, Dang P, Gahche J, Gusev P, Han F, Palachuvattil J, Savarala S, Pehrsson P. Comparison of Labeled Composition and Strength of Prenatal Multivitamin/Mineral (MVM) Prescription (P) and Non‐Prescription (N‐P) Supplements. FASEB J 2015. [DOI: 10.1096/fasebj.29.1_supplement.250.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
26
|
Andrews K, Palachuvattil J, Gusev P, Dang P, Savarala S, Han F, Pehrsson P, Douglass L, Dwyer J, Betz J, Saldanha L, Costello R, Bailey R, Gahche J. Release 3 of the U.S. Dietary Supplement Ingredient Database (DSID): Omega‐3 (n‐3) Fatty Acid and Non‐prescription Prenatal Multivitamin/mineral (MVM) Supplements. FASEB J 2015. [DOI: 10.1096/fasebj.29.1_supplement.250.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- K Andrews
- Nutrient Data LaboratoryUSDABeltsvilleMDUnited States
| | | | - P Gusev
- Nutrient Data LaboratoryUSDABeltsvilleMDUnited States
| | - P Dang
- Nutrient Data LaboratoryUSDABeltsvilleMDUnited States
| | - S Savarala
- Nutrient Data LaboratoryUSDABeltsvilleMDUnited States
| | - F Han
- Nutrient Data LaboratoryUSDABeltsvilleMDUnited States
| | - P Pehrsson
- Nutrient Data LaboratoryUSDABeltsvilleMDUnited States
| | - L Douglass
- Office of Dietary Supplements NIHBethesdaMDUnited States
| | - J Dwyer
- Statistician ConsultantLongmontCOUnited States
| | - J Betz
- Statistician ConsultantLongmontCOUnited States
| | - L Saldanha
- Statistician ConsultantLongmontCOUnited States
| | - R Costello
- Statistician ConsultantLongmontCOUnited States
| | - R Bailey
- Statistician ConsultantLongmontCOUnited States
| | - J Gahche
- National Center for Health Statistics CDCHyattsvilleMDUnited States
| |
Collapse
|
27
|
Decourt A, Couchoud C, Delaroziere J, Gondouin B, Sallée M, Burtey S, Chiche L, Costello R, Dussol B, Brunet P, Berland Y, Jourde-Chiche N. Survie en dialyse chronique des patients atteints de myélome ou d’amylose AL : analyse des données du registre REIN de 2002 à 2011. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.10.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
28
|
Decourt A, Delaroziere J, Couchoud C, Gondouin B, Costello R, Dussol B, Burtey S, Brunet P, Duval A, Sallée M, Berland Y, Jourde-Chiche N. Survie en dialyse chronique des patients atteints de myélome ou d’amylose AL : analyse des données du registre REIN de 2002 à 2011. Nephrol Ther 2014. [DOI: 10.1016/j.nephro.2014.07.307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
29
|
Gusev P, Andrews K, Palachuvattil J, Dang P, Roseland J, Holden J, Savarala S, Pehrsson P, Dwyer J, Betz J, Saldanha L, Bailey R, Costello R, Gahche J, Hardy C, Emenaker N, Douglass L. Over‐the‐counter prenatal multivitamin/mineral products: chemical analysis for the Dietary Supplement Ingredient Database (809.3). FASEB J 2014. [DOI: 10.1096/fasebj.28.1_supplement.809.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P Gusev
- BHNRC‐NDL USDA‐ARSBeltsvilleMDUnited States
| | - K Andrews
- BHNRC‐NDL USDA‐ARSBeltsvilleMDUnited States
| | | | - P Dang
- BHNRC‐NDL USDA‐ARSBeltsvilleMDUnited States
| | - J Roseland
- BHNRC‐NDL USDA‐ARSBeltsvilleMDUnited States
| | - J Holden
- BHNRC‐NDL USDA‐ARSBeltsvilleMDUnited States
| | - S Savarala
- BHNRC‐NDL USDA‐ARSBeltsvilleMDUnited States
| | - P Pehrsson
- BHNRC‐NDL USDA‐ARSBeltsvilleMDUnited States
| | - J Dwyer
- ODS NIHBETHESDAMDUnited States
| | - J Betz
- ODS NIHBETHESDAMDUnited States
| | | | | | | | - J Gahche
- NHANES CDC‐NCHSHyattsvilleMDUnited States
| | - C Hardy
- CFSAN FDACollege ParkMDUnited States
| | | | - L Douglass
- Consulting StatisticianLongmontCOUnited States
| |
Collapse
|
30
|
Saldanha L, Dwyer J, Bailen R, Andrews K, Bailey R, Betz J, Burt V, Chang F, Costello R, Emenaker N, Gahche J, Harnly J, Hardy C, Pehrsson P. When a dietary supplement product name says “energy”, what’s in the bottle? (634.1). FASEB J 2014. [DOI: 10.1096/fasebj.28.1_supplement.634.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - J Dwyer
- ODS/NIHBETHESDAMDUnited States
| | | | | | | | - J Betz
- ODS/NIHBETHESDAMDUnited States
| | - V Burt
- NHANES/CDCHyattsvilleMDUnited States
| | - F Chang
- NLM/NIHBETHESDAMDUnited States
| | | | | | - J Gahche
- NHANES/CDCHyattsvilleMDUnited States
| | - J Harnly
- ARS/USDABeltsvilleMDUnited States
| | - C Hardy
- CFSAN/FDACollege ParkMDUnited States
| | | |
Collapse
|
31
|
Labiad Y, Farnault L, Loriod B, Costello R, Nguyen C. Sepsis and neutropenia in hematological malignancies. Crit Care 2014. [PMCID: PMC4273877 DOI: 10.1186/cc14050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
32
|
Andrews K, Palachuvattil J, Dang P, Gusev P, Savarala S, Pehrsson P, Harnly J, Dwyer J, Betz J, Saldanha L, Bailey R, Costello R, Gahche J, Hardy C, Emenaker N. Botanical initiative for the Dietary Supplement Ingredient Database: green tea pilot study (245.7). FASEB J 2014. [DOI: 10.1096/fasebj.28.1_supplement.245.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- K Andrews
- BHNRC‐NDL USDA‐ARSBeltsvilleMDUnited States
| | | | - P Dang
- BHNRC‐NDL USDA‐ARSBeltsvilleMDUnited States
| | - P Gusev
- BHNRC‐NDL USDA‐ARSBeltsvilleMDUnited States
| | - S Savarala
- BHNRC‐NDL USDA‐ARSBeltsvilleMDUnited States
| | - P Pehrsson
- BHNRC‐NDL USDA‐ARSBeltsvilleMDUnited States
| | - J Harnly
- BHNRC‐FCMDL USDA‐ARSBeltsvilleMDUnited States
| | - J Dwyer
- ODS NIHBETHESDAMDUnited States
| | - J Betz
- ODS NIHBETHESDAMDUnited States
| | | | | | | | - J Gahche
- NHANES CDC‐NCHSHyattsvilleMDUnited States
| | - C Hardy
- CFSAN FDA CollegeParkMDUnited States
| | | |
Collapse
|
33
|
Brun M, Mazodier K, Farnault L, Harle JR, Chetaille B, Costello R, Kaplanski G. Premier cas de syndrome d’activation macrophagique secondaire à une hépatite virale E (VHE) chez un patient atteint d’un lymphome splénique. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.03.019] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
34
|
Costello R, Lecine P, Kahn-Perlès B, Algarté M, Lipcey C, Olive D, Imbert J. Activation du système de facteurs de transcription Rel/NF-κB. ACTA ACUST UNITED AC 2013. [DOI: 10.4267/10608/2395] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
35
|
Murphy O, O'Connell O, Liston R, Connaughton J, Costello R, Breiden J, Doran P, Gaine S. Venous thromboembolism risk and prophylaxis in the acute hospital care setting: the Irish results of the ENDORSE study. Ir Med J 2012; 105:140-143. [PMID: 22803491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
ENDORSE (Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting), is a multinational, cross-sectional survey of venous thromboembolism (VTE) risk prevalence and effective prophylaxis in the acute hospital care setting. Three Irish hospitals enrolled in the study. The American College of Chest Physicians (ACCP) guidelines were employed to evaluate VTE risk and prophylaxis. Of 552 patients, 297 (53.8%) and 255 (46.2%) were categorised as surgical or medical, respectively, with 175 (59%) surgical and 109 (43%) medical patients deemed to be at risk for VTE. Of these, only 112 (64%) and 51 (47%) received recommended VTE prophylaxis, respectively. The results are consistent with those observed in other countries and demonstrate a high prevalence of risk for VTE and a low rate of prophylaxis use, particularly in medical patients. Awareness of VTE guidelines should be an integral component of health policy.
Collapse
Affiliation(s)
- O Murphy
- Department of Respiratory Medicine, Cork University Hospital, Wilton, Cork
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Costello R, Huret G, Sappa E, Bergoin-Costello V. [Automated screening for transfusionnal hemochromatosis]. Transfus Clin Biol 2012; 19:57-9. [PMID: 22503459 DOI: 10.1016/j.tracli.2012.01.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2011] [Accepted: 01/24/2012] [Indexed: 11/27/2022]
Abstract
Post-transfusion hemochromatosis is a major concern in patients with chronic transfusion (i.e. more than 20 red blood cell concentrates). While the monitoring of infectious complications and transfusion accidents is clearly one of the missions of haemovigilance, hemochromatosis is not yet subject to such a systematic monitoring. We therefore wanted to assess the incidence of this complication in the context of a general hospital (hospital of Aix) and propose the establishment of a screening and a comprehensive monitoring of post transfusion hemochromatosis.
Collapse
Affiliation(s)
- R Costello
- Service d'hématologie, CHU La Conception, Marseille, France
| | | | | | | |
Collapse
|
37
|
Brun M, Moucadel M, Cristea A, Mazodier K, Genot S, Costello R, Harle JR, Kaplanski G. Sarcoïdose pulmonaire pseudo-tumorale : à propos de deux cas. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
38
|
Costello R. Hypertension artérielle pulmonaire et hémopathies malignes. Rev Med Interne 2010; 31:621-5. [DOI: 10.1016/j.revmed.2009.06.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2009] [Revised: 05/01/2009] [Accepted: 06/22/2009] [Indexed: 12/15/2022]
|
39
|
Thuny C, Gaudy-Marqueste C, Nicol I, Gabert J, Costello R, Grob JJ, Richard MA. Chronic eosinophilic leukaemia revealed by lymphomatoid papulosis: the role of the FIP1-like 1-platelet-derived growth factor receptor alpha fusion gene. J Eur Acad Dermatol Venereol 2009; 24:234-5. [PMID: 19686260 DOI: 10.1111/j.1468-3083.2009.03382.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
40
|
Costello R. Actualités sur les thalassémies. Rev Med Interne 2009. [DOI: 10.1016/j.revmed.2009.02.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
41
|
Shen S, Nabors LB, Raizer JJ, Fiveash JB, Spies S, Costello R, O’Neill AM. Dosimetry study of a phase II multiple-dose intracavitary administration of 131I-TM601 in adult patients with recurrent high-grade glioma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e13006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13006 Background: Postoperative radiotherapy for glioma has been shown to improve survival with increased radiation doses. Dose escalation of external beam radiotherapy or brachytherapy is limited by normal brain radionecrosis. Radiolabeled targeting molecules can deliver localized radiation to tumor and reduce normal brain radionecrosis. TM601, or synthetic Chlorotoxin, is a peptide derived from scorpion venom that specifically binds to tumor cells. Here we report dosimetry results of an imaging sub-study of a phase II trial, in which weekly doses of 131I-TM601 were infused into surgically created tumor resection cavities for 3 or 6 weeks. Methods: Five out of 76 patients treated in a phase II trial were imaged after receiving 1, 3, or 6 doses of 40 mCi/0.8 mg 131I-TM601 intracavitarily. For each imaging study, 5 sequential SPECT images (1–168 hour) were registered with MRI to determine the 131I-TM601 radiation dose to the 2-cm tumor cavity margin. Five sequential body scans were also acquired to determine 131I-TM601 radiation dose to extra-cranial organs. Results: 131I-TM601 is a rapidly penetrating and clearing radiolabeled peptide. The median residual activity in the cavity at 7 days post injection was 8.4%. Median radiation dose to the cavity margin was 121 cGy/mCi and ranged 52- 338 cGy/mCi in 5 subjects. The median coefficient of variation (intra-patient inter-fraction) for the 2-cm margin dose was 14.7% and ranged 7.1–18.9%. Median tumor cavity volume was 11.4 mL, and ranged 5.2 - 35.5 mL. There was no observed correlation between the 2-cm margin dose and the cavity volume. Median radiation dose to thyroid, kidneys, red marrow, and body was 8.3, 1.3, 0.4, and 0.6 cGy/mCi, respectively. Conclusions: Radiation dose ratio for 2-cm cavity margin-to-normal tissues was quite high. While intra-patient reproducibility was relatively good, cumulative effect of the residual activity was only meaningful within a week. These results support the multi-dose fractionation scheme for 131I-TM601 to minimize normal tissue toxicity, including radiation necrosis, and extend continuous irradiation to clinical or sub-clinical residual tumor cells after surgery. [Table: see text]
Collapse
Affiliation(s)
- S. Shen
- University of Alabama at Birmingham, Birmingham, AL; Northwestern University, Chicago, IL; Northwestern Memorial Hospital, Chicago, IL; TransMolecular, Inc., Cambridge, MA
| | - L. B. Nabors
- University of Alabama at Birmingham, Birmingham, AL; Northwestern University, Chicago, IL; Northwestern Memorial Hospital, Chicago, IL; TransMolecular, Inc., Cambridge, MA
| | - J. J. Raizer
- University of Alabama at Birmingham, Birmingham, AL; Northwestern University, Chicago, IL; Northwestern Memorial Hospital, Chicago, IL; TransMolecular, Inc., Cambridge, MA
| | - J. B. Fiveash
- University of Alabama at Birmingham, Birmingham, AL; Northwestern University, Chicago, IL; Northwestern Memorial Hospital, Chicago, IL; TransMolecular, Inc., Cambridge, MA
| | - S. Spies
- University of Alabama at Birmingham, Birmingham, AL; Northwestern University, Chicago, IL; Northwestern Memorial Hospital, Chicago, IL; TransMolecular, Inc., Cambridge, MA
| | - R. Costello
- University of Alabama at Birmingham, Birmingham, AL; Northwestern University, Chicago, IL; Northwestern Memorial Hospital, Chicago, IL; TransMolecular, Inc., Cambridge, MA
| | - A. M. O’Neill
- University of Alabama at Birmingham, Birmingham, AL; Northwestern University, Chicago, IL; Northwestern Memorial Hospital, Chicago, IL; TransMolecular, Inc., Cambridge, MA
| |
Collapse
|
42
|
Mohammad A, Ambrose N, Tuohy M, Conway R, Costello R, Kearns G. Relapsing polychondritis: reversible airway obstruction or asthma. Clin Exp Rheumatol 2008; 26:938-940. [PMID: 19032834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
We describe a patient who presented with poorly controlled asthma. Bronchoscopy showed collapsing airways, characteristic of RP (relapsing polychondritis).
Collapse
Affiliation(s)
- A Mohammad
- Departments of Rheumatology, Beaumont Hospital, Dublin, Ireland.
| | | | | | | | | | | |
Collapse
|
43
|
Wirth LJ, Posner MR, Tishler RB, Haddad RI, Clark JR, Goguen L, Norris CM, Annino D, Costello R, Allen AM. Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.6007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
44
|
Tishler RB, Posner MR, Wirth LJ, Balboni T, Costello R, Goguen L, Annino D, Livada N, Norris CM, Haddad RI. Cetuximab added to docetaxel, cisplatin, 5-fluorouracil Induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.6001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Walsh MT, Costello R. Putting fat on the fire? Lysophospholipid mediators in bronchoalveolar lavage fluid after allergen challenge. Clin Exp Allergy 2007; 37:305-7. [PMID: 17359379 DOI: 10.1111/j.1365-2222.2007.02674.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
46
|
Abstract
We present the case of a rare entity which is a complication of a disease process that had almost disappeared from the Western World. With the recent resurgence in reported cases of Mycobacterium tuberculosis (TB) in Western communities, it is important to recognize complications and sequelae. A young alcoholic male with confirmed active TB suffered a cardiac arrest following massive haemoptysis. Multidetector computed tomography angiography diagnosed a Rasmussen's aneurysm, confirmed by digital subtraction angiography and then successfully embolized with glue. We outline this rare case and the embolization technique and review previously documented reports.
Collapse
MESH Headings
- Adult
- Alcoholism/complications
- Aneurysm, False/complications
- Aneurysm, False/diagnosis
- Aneurysm, False/therapy
- Angiography, Digital Subtraction
- Blood Transfusion
- Cyanoacrylates/therapeutic use
- Embolization, Therapeutic/methods
- Heart Arrest/complications
- Heart Arrest/therapy
- Hemoglobins
- Hemoptysis/etiology
- Humans
- Hypoxia, Brain/etiology
- Intubation, Intratracheal
- Male
- Mycobacterium tuberculosis/isolation & purification
- Pulmonary Artery/diagnostic imaging
- Rare Diseases
- Respiration, Artificial
- Severity of Illness Index
- Treatment Outcome
- Tuberculosis, Pulmonary/complications
- Tuberculosis, Pulmonary/drug therapy
Collapse
Affiliation(s)
- A N Keeling
- Department of Academic Radiology, Beaumont Hospital, Dublin 9, Ireland
| | | | | |
Collapse
|
47
|
Burke E, Goguen L, Tishler R, Wirth L, Posner M, Hempel E, Allen A, Costello R, Haddad R. Impact of chemoradiotherapy for locally advanced head and neck cancer on swallowing function. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.6054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6054 Background: We examined the impact of chemoradiotherapy (CRT) on swallowing function in a group of patients treated for locally advanced head and neck cancer in an ongoing randomized phase II study with concurrent CRT, with or without Ethyol. Methods: Chemotherapy consisted of weekly carboplatin AUC 1.5 and paclitaxel at 45 /m2 for 4 weeks. Radiation was delivered using a 3 field technique with a concomitant boost schedule to a total dose of 72 Gy. Patients were randomized to receive or not receive daily subcutaneous Ethyol. Patients had video swallow studies at the start of radiation and 8, 12, 24 and 52 weeks post chemoradiotherapy. Dysphagia and weight loss were monitored. Video swallow study reports were collected and the incidence of penetration, aspiration, pharyngeal residue and upper esophageal narrowing analyzed. Results: Baseline data were available for 31 patients out of 43 enrolled. 29% of the patients penetrated, 6.4% aspirated and 29% had pharyngeal residue. Patients on both arms of the study had a steady decline in swallowing function from onset until 24 weeks post radiation. Penetration, aspiration and pharyngeal residue were consistently noted at all time points and improvements in deglutition were seen on the 52-week post radiation video swallow. Forty percent of the patients (17/43) had narrowing in the upper esophagus. On average, a third of the patients examined required dilations. The remaining patients with esophageal narrowing were able to advance their diet and have their feeding tubes removed without dilations. The average time from the end of the treatment to PEG removal was 219 days. Conclusion: Based on the video swallow studies that were conducted, patients had a gradual decline in swallowing function from initiation of CRT until 24 weeks post. Esophageal narrowing was common, often requiring dilation. Given that it takes 7 months on average for the feeding tubes to come out, we recommend that these patients undergo intensive swallowing therapy and continuous long term follow up and assessment at two and possibly three years post CRT. Study is ongoing. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. Burke
- Dana-Farber Cancer Institute, Boston, MA
| | - L. Goguen
- Dana-Farber Cancer Institute, Boston, MA
| | - R. Tishler
- Dana-Farber Cancer Institute, Boston, MA
| | - L. Wirth
- Dana-Farber Cancer Institute, Boston, MA
| | - M. Posner
- Dana-Farber Cancer Institute, Boston, MA
| | - E. Hempel
- Dana-Farber Cancer Institute, Boston, MA
| | - A. Allen
- Dana-Farber Cancer Institute, Boston, MA
| | | | - R. Haddad
- Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
48
|
Lucey D, Walsh M, Costello R. The role of platelet-derived lysophospholipids in the progression of head and neck cancer. Clin Otolaryngol 2006. [DOI: 10.1111/j.1365-2273.2006.01341_3.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
49
|
Aissi K, Rossi P, Le TBV, Granel B, Bagnères D, Demoux AL, Bonin-Guillaume S, Costello R, Sebahoun G, Francès Y. [Necrotic myocarditis in acute eosinophilic lymphoblastic leukaemia]. Rev Med Interne 2006; 27:869-73. [PMID: 16949707 DOI: 10.1016/j.revmed.2006.07.018] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2005] [Revised: 06/18/2006] [Accepted: 07/23/2006] [Indexed: 11/27/2022]
Abstract
INTRODUCTION Hypereosinophilia can cause severe cardiac complications. The association between an acute lymphoblastic leukemia and hypereosinophilia was rare. We report a case of a 29-year-old man who presented a heart failure secondary to necrotic myocarditis related to an acute eosinophilic lymphoblastic leukaemia. EXEGESIS The patient developed a heart failure and secondary a cardio-embolic stroke, due to a large mobile left ventricle thrombosis. His peripheral blood showed a total white count of 28,500 leucocytes/mm3 with 18,800 eosinophils/mm3. The myelogram cytology showed precursor B-cell acute lymphoblastic leukaemia with hypereosinophilia. CONCLUSION The possibility of the rapid emergence of cardiac lesions in hypereosinophilic syndromes warrants very close physician vigilance. An Echocardiography and MRI performed at the early stage and in the follow-up allow to detect and to manage these cardiac disorders.
Collapse
Affiliation(s)
- K Aissi
- Service de médecine interne, APHM, CHU Nord, chemin des Bourrely, 13326 Marseille cedex 20, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Fitzgerald M, Costello R. Book review. Ir J Med Sci 2006. [DOI: 10.1007/bf03169180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|